
    
      A cohort of patients (Cohort 1) will be enrolled to receive the currently accepted standard
      approach to myeloablative allogeneic stem cell transplantation. With the exception of volume
      and/or plasma depletion (in cases of donor/recipient ABO incompatibility), the peripheral
      blood stem cell graft will be unmodified. The primary purpose of Cohort 1 is to prospectively
      collect samples for measurement of immune recovery from a relatively homogeneous population
      of patients treated in a uniform manner. Within the limitations of age-matching, patients
      accrued to Cohort 1 will be incorporated into a larger retrospective historical control group
      for purposes of comparison with Cohort 2 of the incidence of grade II-IV acute Graft versus
      Host disease. The experimental aspects of this trial will be the use of a na√Øve T-cell
      depleted peripheral blood stem cell graft (Cohort 2). All other aspects of this stem cell
      transplantation are in line with the standard of care. Recruitment to this trial will be
      stratified by donor type as matched sibling or matched unrelated donor. Patients will be
      conditioned with total body irradiation (1350cGy) and Cyclophosphamide. The donor stem cell
      grafts will come from mobilized peripheral blood of 6/6 HLA-identical family members or 8/8
      (HLA A, B, C, DRB1) allele-level matched unrelated donors.
    
  